Long-term outcome of esthesioneuroblastoma

Hyams grade predicts patient survival

Jamie Van Gompel, Caterina Giannini, Kerry D. Olsen, Eric Moore, Manolo Piccirilli, Robert L. Foote, Jan Craig Buckner, Michael J. Link

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

Object: Esthesioneuroblastoma (ENB) is a rare malignant neuroendocrine tumor originating from the olfactory neuroepithelium in the cribriform plate. Controversy still exists regarding the role of pathologic grading (Hyams grade) in prognostication. This study was undertaken to describe our experience with ENB and assess the role of pathologic grading in patient outcome. Methods: This was a retrospective, single-institution experience, including 109 patients with ENB treated at our institution from 1962 to 2009. Multivariate analysis was performed utilizing Cox regression analysis models utilizing age, gender, modified Kadish stage, and Hyams grade. Results: Mean age was 49 ± 16 (median 50) years at presentation (range 12 to 90 years). Median follow up was 5.1 years. All-cause mortality was significantly in fluenced by Hyams grading in univariate (p = 0.04) and multivariate (p = 0.02) analysis, in addition to proven prognostic factors, Kadish staging, lymph node metastasis, and age. Median survival was 9.8 years compared with 6.9 years with low (grade 1 to 2) versus high (grade 3 to 4) Hyams grade. Median overall survival was 7.2 ± 0.7 years. Conclusion: ENB has a variable outcome, which is primarily prognosticated by the extent of involvement at presentation (Kadish stage and lymph node metastasis) and higher Hyams pathologic grade.

Original languageEnglish (US)
Pages (from-to)331-336
Number of pages6
JournalJournal of Neurological Surgery, Part B: Skull Base
Volume73
Issue number5
DOIs
StatePublished - 2012

Fingerprint

Olfactory Esthesioneuroblastoma
Survival
Lymph Nodes
Ethmoid Bone
Neoplasm Metastasis
Neuroendocrine Tumors
Multivariate Analysis
Regression Analysis
Mortality

Keywords

  • Esthesioneuroblastoma
  • Hyams grade
  • Olfactory neuroblastoma
  • Outcome
  • Surgical treatment

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Long-term outcome of esthesioneuroblastoma : Hyams grade predicts patient survival. / Van Gompel, Jamie; Giannini, Caterina; Olsen, Kerry D.; Moore, Eric; Piccirilli, Manolo; Foote, Robert L.; Buckner, Jan Craig; Link, Michael J.

In: Journal of Neurological Surgery, Part B: Skull Base, Vol. 73, No. 5, 2012, p. 331-336.

Research output: Contribution to journalArticle

Van Gompel, Jamie ; Giannini, Caterina ; Olsen, Kerry D. ; Moore, Eric ; Piccirilli, Manolo ; Foote, Robert L. ; Buckner, Jan Craig ; Link, Michael J. / Long-term outcome of esthesioneuroblastoma : Hyams grade predicts patient survival. In: Journal of Neurological Surgery, Part B: Skull Base. 2012 ; Vol. 73, No. 5. pp. 331-336.
@article{a5d0c50bea3e4f7199d3f3bd158e2d78,
title = "Long-term outcome of esthesioneuroblastoma: Hyams grade predicts patient survival",
abstract = "Object: Esthesioneuroblastoma (ENB) is a rare malignant neuroendocrine tumor originating from the olfactory neuroepithelium in the cribriform plate. Controversy still exists regarding the role of pathologic grading (Hyams grade) in prognostication. This study was undertaken to describe our experience with ENB and assess the role of pathologic grading in patient outcome. Methods: This was a retrospective, single-institution experience, including 109 patients with ENB treated at our institution from 1962 to 2009. Multivariate analysis was performed utilizing Cox regression analysis models utilizing age, gender, modified Kadish stage, and Hyams grade. Results: Mean age was 49 ± 16 (median 50) years at presentation (range 12 to 90 years). Median follow up was 5.1 years. All-cause mortality was significantly in fluenced by Hyams grading in univariate (p = 0.04) and multivariate (p = 0.02) analysis, in addition to proven prognostic factors, Kadish staging, lymph node metastasis, and age. Median survival was 9.8 years compared with 6.9 years with low (grade 1 to 2) versus high (grade 3 to 4) Hyams grade. Median overall survival was 7.2 ± 0.7 years. Conclusion: ENB has a variable outcome, which is primarily prognosticated by the extent of involvement at presentation (Kadish stage and lymph node metastasis) and higher Hyams pathologic grade.",
keywords = "Esthesioneuroblastoma, Hyams grade, Olfactory neuroblastoma, Outcome, Surgical treatment",
author = "{Van Gompel}, Jamie and Caterina Giannini and Olsen, {Kerry D.} and Eric Moore and Manolo Piccirilli and Foote, {Robert L.} and Buckner, {Jan Craig} and Link, {Michael J.}",
year = "2012",
doi = "10.1055/s-0032-1321512",
language = "English (US)",
volume = "73",
pages = "331--336",
journal = "Journal of Neurological Surgery, Part B: Skull Base",
issn = "2193-6331",
publisher = "Thieme Medical Publishers",
number = "5",

}

TY - JOUR

T1 - Long-term outcome of esthesioneuroblastoma

T2 - Hyams grade predicts patient survival

AU - Van Gompel, Jamie

AU - Giannini, Caterina

AU - Olsen, Kerry D.

AU - Moore, Eric

AU - Piccirilli, Manolo

AU - Foote, Robert L.

AU - Buckner, Jan Craig

AU - Link, Michael J.

PY - 2012

Y1 - 2012

N2 - Object: Esthesioneuroblastoma (ENB) is a rare malignant neuroendocrine tumor originating from the olfactory neuroepithelium in the cribriform plate. Controversy still exists regarding the role of pathologic grading (Hyams grade) in prognostication. This study was undertaken to describe our experience with ENB and assess the role of pathologic grading in patient outcome. Methods: This was a retrospective, single-institution experience, including 109 patients with ENB treated at our institution from 1962 to 2009. Multivariate analysis was performed utilizing Cox regression analysis models utilizing age, gender, modified Kadish stage, and Hyams grade. Results: Mean age was 49 ± 16 (median 50) years at presentation (range 12 to 90 years). Median follow up was 5.1 years. All-cause mortality was significantly in fluenced by Hyams grading in univariate (p = 0.04) and multivariate (p = 0.02) analysis, in addition to proven prognostic factors, Kadish staging, lymph node metastasis, and age. Median survival was 9.8 years compared with 6.9 years with low (grade 1 to 2) versus high (grade 3 to 4) Hyams grade. Median overall survival was 7.2 ± 0.7 years. Conclusion: ENB has a variable outcome, which is primarily prognosticated by the extent of involvement at presentation (Kadish stage and lymph node metastasis) and higher Hyams pathologic grade.

AB - Object: Esthesioneuroblastoma (ENB) is a rare malignant neuroendocrine tumor originating from the olfactory neuroepithelium in the cribriform plate. Controversy still exists regarding the role of pathologic grading (Hyams grade) in prognostication. This study was undertaken to describe our experience with ENB and assess the role of pathologic grading in patient outcome. Methods: This was a retrospective, single-institution experience, including 109 patients with ENB treated at our institution from 1962 to 2009. Multivariate analysis was performed utilizing Cox regression analysis models utilizing age, gender, modified Kadish stage, and Hyams grade. Results: Mean age was 49 ± 16 (median 50) years at presentation (range 12 to 90 years). Median follow up was 5.1 years. All-cause mortality was significantly in fluenced by Hyams grading in univariate (p = 0.04) and multivariate (p = 0.02) analysis, in addition to proven prognostic factors, Kadish staging, lymph node metastasis, and age. Median survival was 9.8 years compared with 6.9 years with low (grade 1 to 2) versus high (grade 3 to 4) Hyams grade. Median overall survival was 7.2 ± 0.7 years. Conclusion: ENB has a variable outcome, which is primarily prognosticated by the extent of involvement at presentation (Kadish stage and lymph node metastasis) and higher Hyams pathologic grade.

KW - Esthesioneuroblastoma

KW - Hyams grade

KW - Olfactory neuroblastoma

KW - Outcome

KW - Surgical treatment

UR - http://www.scopus.com/inward/record.url?scp=84904284263&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904284263&partnerID=8YFLogxK

U2 - 10.1055/s-0032-1321512

DO - 10.1055/s-0032-1321512

M3 - Article

VL - 73

SP - 331

EP - 336

JO - Journal of Neurological Surgery, Part B: Skull Base

JF - Journal of Neurological Surgery, Part B: Skull Base

SN - 2193-6331

IS - 5

ER -